Table 2. Biologics targeting lymphotoxin signalling for the treatment of cancers and autoimmune diseases.
| Target molecule | Species | Type of agent | Disease/model | Trade name | Stage of clinical development | Reference |
|---|---|---|---|---|---|---|
| Cancer | ||||||
| LTα | Mouse | Antibody-LTα fusion protein | Melanoma | — | — | 24, 80 |
| LTβR | Mouse | α-LTβR agonist antibody | Colon carcinoma | — | — | 81, 82 |
| α-LTβR neutralizing antibody | Sarcoma, Breast cancer | — | — | 83 | ||
| Adenovirus expressing LIGHT | Fibrosarcoma, Colon carcinoma, Breast cancer, Prostate cancer | — | — | 77, 84, 85, 86 | ||
| LIGHT | Mouse | Salmonella expressing LIGHT | Lymphoma | — | — | 87 |
| Antibody-LIGHT fusion protein | Fibrosarcoma, Colon carcinoma | — | — | 103 | ||
| Autoimmune disease | ||||||
| LTα/LTβ | Mouse | α-LTα antibody | RA, EAE | — | — | 88 |
| α-LTβ antibody | EAE | — | — | 89 | ||
| Human | α-LTα antibody | RA | Pateclizumab | Phase 2 (discontinued) | 90 | |
| LTβR | Mouse | LTβR-Ig fusion protein | RA, IBD, EAE, T1D, SS | — | — | 89, 91, 92, 93, 94, 95, 96 |
| Human | LTβR-Ig fusion protein | RA | Baminercept | Phase 2 (discontinued) | 97, 98 | |
| SS | Baminercept | Phase 2 | 99 | |||
| LIGHT | Human | α-LIGHT antibody | Crohn's disease, Ulcerative colitis | SAR252067 | Phase 1 (discontinued) | Sanofi 1Q 2015 report |
| IBD | SAR252067 | Phase 1 | 100 | |||
Abbreviations: EAE, Experimental autoimmune encephalomyelitis; IBD, Inflammatory bowel disease; RA, Rheumatoid arthritis; SS, Sjogren’s syndrome; T1D, Type 1 diabetes.